Acrux Ltd

Healthcare AU ACR

0.079AUD
-(-%)

Last update at 2024-06-14T00:00:00Z

Day Range

0.080.08
LowHigh

52 Week Range

0.040.09
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -0.21200M -9.58200M -12.43200M -9.38500M -8.33500M
Minority interest - - - - -
Net income -0.76400M -9.83400M -12.62900M -9.47100M -8.32500M
Selling general administrative 5.77M 6.08M 6.36M 5.94M 6.21M
Selling and marketing expenses - - - - -
Gross profit 7.87M -4.65200M -7.59100M -3.75900M 0.63M
Reconciled depreciation 0.59M 0.66M 0.67M 0.71M 0.43M
Ebit -3.06900M -12.96600M -16.25100M -12.07700M -12.99000M
Ebitda -2.47400M -12.30600M -15.58600M -11.36900M -12.56400M
Depreciation and amortization 0.59M 0.66M 0.67M 0.71M 0.43M
Non operating income net other - - - - -
Operating income -3.39000M -12.96600M -16.25100M -12.07700M -12.99000M
Other operating expenses 8.76M 11.32M 13.80M 10.85M 13.62M
Interest expense - 0.02M 3.82M 2.69M 4.66M
Tax provision 0.55M 0.25M 0.20M 0.09M -0.01000M
Interest income 0.12M 0.02M 0.03M 0.22M 0.58M
Net interest income 0.12M 0.02M 0.03M 0.22M 0.58M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.55M 0.25M 0.20M 0.09M -0.01000M
Total revenue 8.43M 1.72M 1.34M 1.25M 0.63M
Total operating expenses 11.26M 14.69M 17.59M 13.33M 13.62M
Cost of revenue 0.56M 6.37M 8.93M 5.01M 5.12M
Total other income expense net 3.06M 3.37M 3.79M 2.48M 4.66M
Discontinued operations - - - - -
Net income from continuing ops -0.76400M -9.83400M -12.62900M -9.47100M -8.32500M
Net income applicable to common shares -0.76400M -9.83400M -12.62900M -9.47100M -8.32500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 13.29M 14.30M 23.33M 17.84M 24.43M
Intangible assets 0.00000M 0.38M 0.48M 0.59M 0.70M
Earning assets - - - - -
Other current assets 0.04M 3.92M 3.04M 2.95M 0.49M
Total liab 4.59M 5.21M 4.86M 4.99M 2.50M
Total stockholder equity 8.70M 9.09M 18.47M 12.85M 21.94M
Deferred long term liab - 0.38M 0.48M 0.59M 0.70M
Other current liab 1.90M 2.53M 2.45M 1.64M 1.51M
Common stock 114.88M 114.56M 114.21M 96.14M 95.88M
Capital stock 114.88M 114.56M 114.21M 96.14M 95.88M
Retained earnings -114.48700M -113.72300M -103.88900M -83.87000M -74.58200M
Other liab 0.04M 0.04M 0.04M 0.09M 0.08M
Good will - - - - -
Other assets 0.80M 1.73M 2.09M 2.39M 2.59M
Cash 6.23M 5.83M 15.27M 9.21M 18.15M
Cash and equivalents 3.00M 3.00M 8.00M 8.00M 18.00M
Total current liabilities 2.39M 3.32M 2.77M 2.67M 2.42M
Current deferred revenue -0.19200M -0.22400M -0.18500M -0.16700M -0.16700M
Net debt -3.87900M -3.75300M -13.03600M -6.80500M -15.75100M
Short term debt 0.19M 0.22M 0.18M 0.17M 0.17M
Short long term debt - - - - -
Short long term debt total 2.35M 2.08M 2.23M 2.40M 2.40M
Other stockholder equity 0.91M 0.86M 0.76M 2.80M 2.48M
Property plant equipment 2.59M 2.56M 2.64M 3.10M 0.91M
Total current assets 9.89M 10.02M 18.59M 12.34M 20.94M
Long term investments - - - - -
Net tangible assets 8.70M 9.09M 18.47M 12.85M 21.94M
Short term investments - - - - -
Net receivables 3.31M 3.77M 3.16M 2.56M 2.30M
Long term debt - - - - -
Inventory 0.32M 0.00000M -2.87100M -2.36900M -
Accounts payable 0.49M 0.79M 0.31M 1.02M 0.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 8.30M 8.25M 8.15M 0.58M 0.64M
Additional paid in capital - - - - -
Common stock total equity - - - 96.14M 95.88M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -2.55600M -2.64400M -3.10000M 3.49M
Deferred long term asset charges - - - - -
Non current assets total 3.39M 4.29M 4.73M 5.49M 3.49M
Capital lease obligations 2.35M 2.08M 2.23M 2.40M -
Long term debt total 2.16M 1.85M 2.05M 2.23M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.11900M -0.46500M -0.10200M -0.25400M -0.38000M
Change to liabilities -0.29500M 0.69M 0.09M 0.09M -0.09600M
Total cashflows from investing activities -0.11900M -0.46500M -0.10200M -0.25400M -0.38000M
Net borrowings -0.18300M -0.15500M -0.16700M -0.15900M -0.15900M
Total cash from financing activities -0.18300M -0.15500M 17.58M -0.15900M -0.15900M
Change to operating activities 0.02M -0.18200M 0.55M -0.00100M -0.23800M
Net income -0.76400M -9.83400M -12.62900M -9.47100M -8.32500M
Change in cash 0.40M -9.43900M 6.06M -8.94600M -10.31800M
Begin period cash flow 5.83M 15.27M 9.21M 18.15M 28.47M
End period cash flow 6.23M 5.83M 15.27M 9.21M 18.15M
Total cash from operating activities 0.70M -8.81900M -11.41400M -8.53300M -9.93800M
Issuance of capital stock - - 17.75M - -
Depreciation 0.86M 0.55M 0.56M 0.60M 0.43M
Other cashflows from investing activities - - 0.00000M 0.00400M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.46M -0.60600M -0.60000M -0.24600M -2.04000M
Sale purchase of stock - 0.00000M 17.75M - -
Other cashflows from financing activities -0.11900M -0.46500M -0.10200M -0.25400M -0.15900M
Change to netincome 0.37M 0.45M 0.51M 0.39M 0.28M
Capital expenditures 0.12M 0.47M 0.10M 0.26M 0.38M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.46M -0.60600M -0.60000M -0.24600M 2.67M
Stock based compensation 0.37M 0.45M 0.51M 0.39M -
Other non cash items 0.60M 0.46M 0.66M 0.34M 7.90M
Free cash flow 0.58M -9.28400M -11.51600M -8.79100M -0.38000M

Fundamentals

  • Previous Close 0.08
  • Market Cap22.97M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.17000M
  • Revenue TTM11.42M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 4.06M
  • Diluted EPS TTM-

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACR
Acrux Ltd
- -% 0.08 - - 1.60 3.25 1.40 -7.4254
CSL
CSL Ltd
0.43 0.15% 288.39 37.40 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd
0.12 0.73% 16.58 823.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd
0.45 2.33% 19.76 16.09 38.46 11.63 13.15 10.65 12.39
CU6
Clarity Pharmaceuticals Ltd
0.04 0.75% 5.40 - - 85.90 15.59 - -18.7407

Reports Covered

Stock Research & News

Profile

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Acrux Ltd

103-113, Stanley Street, West Melbourne, VIC, Australia, 3003

Key Executives

Name Title Year Born
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO, MD & Exec. Director 1966
Ms. Joanna Johnson B.E., BEc, ICAA CFO & Company Sec. NA
Ms. Felicia Colagrande B.Sc., BSc (Hons), M.B.A., MBA Product Devel. & Technical Affairs Director NA
Mr. Charles O'Sullivan B. Pharm Portfolio Director NA
Mr. Mark Hyman Project & Technical Devel. Director NA
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO, MD & Executive Director 1966
Ms. Joanna Johnson B.E., BEc, ICAA CFO & Company Secretary NA
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO, MD & Executive Director 1966
Ms. Joanna Johnson B.E., BEc, ICAA CFO & Company Secretary NA
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO, MD & Executive Director 1966

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).